Loading…

Design, Synthesis, and Biological Investigation of Thailanstatin A and Spliceostatin D Analogues Containing Tetrahydropyran, Tetrahydrooxazine, and Fluorinated Structural Motifs

Thailanstatin A and spliceostatin D, two naturally occurring molecules endowed with potent antitumor activities by virtue of their ability to bind and inhibit the function of the spliceosome, and their natural siblings and designed analogues, constitute an appealing family of compounds for further e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of organic chemistry 2021-02, Vol.86 (3), p.2499-2521
Main Authors: Nicolaou, K. C, Rekula, Santhosh Reddy, Kumar, S. Mothish, Podilapu, Ananda Rao, Matuszak, Ryan P, Jung, Paul M, Lam, Lloyd T, Phillips, Andrew C, Lyssikatos, Joseph, Munneke, Stefan, Gu, Christine, Sarvaiya, Hetal, Sandoval, Joseph, Hammond, Mikhail, Aujay, Monette, Purcell, James W, Reilly, Regina M, Gavrilyuk, Julia
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thailanstatin A and spliceostatin D, two naturally occurring molecules endowed with potent antitumor activities by virtue of their ability to bind and inhibit the function of the spliceosome, and their natural siblings and designed analogues, constitute an appealing family of compounds for further evaluation and optimization as potential drug candidates for cancer therapies. In this article, the design, synthesis, and biological investigation of a number of novel thailanstatin A analogues, including some accommodating 1,1-difluorocyclopropyl and tetrahydrooxazine structural motifs within their structures, are described. Important findings from these studies paving the way for further investigations include the identification of several highly potent compounds for advancement as payloads for antibody–drug conjugates (ADCs) as potential targeted cancer therapies and/or small molecule drugs, either alone or in combination with other anticancer agents.
ISSN:0022-3263
1520-6904
DOI:10.1021/acs.joc.0c02643